Disorder

• Name: Hemophilia B
• Category: Genetic
• Existing deep-research providers: falcon, perplexity
• Existing evidence reference count in YAML: 15

Key Pathophysiology Nodes

• Factor IX Deficiency
• Deep research literature mapping

Citation Inventory (for evidence mapping)

• DOI:10.1002/14651858.cd014544.pub2
• DOI:10.1007/s13353-025-00952-w
• DOI:10.1007/s40140-024-00635-y
• DOI:10.1016/s0140-6736(24
• DOI:10.1056/nejmoa2302982
• DOI:10.1111/j.1365-2516.2005.01123.x
• DOI:10.1186/s13052-024-01819-2
• DOI:10.14302/issn.2372-6601.jhor-24-5108
• DOI:10.3389/fmed.2025.1618464
• DOI:10.3390/biom14070854
• DOI:10.57582/ijbf.250502.066

Pathophysiology description Hemophilia B (HB) is an X‑linked recessive bleeding disorder caused by pathogenic variants in the F9 gene leading to reduced or absent factor IX (FIX) activity, impairing intrinsic tenase formation (FVIIIa–FIXa complex) and downstream thrombin generation. Disease severity correlates with residual FIX activity: severe <1%, moderate 1–5%, mild 5–40% of normal; prevalence is approximately 1 in 30,000 males worldwide (clinical phenotype typically includes mucocutaneous bleeding, post‑procedural hemorrhage, hemarthroses) (baniamer2024understandinginheritedbleeding pages 2-4). FVIII/FIX function can be conceptualized through tenase biology; notably, the approved bispecific antibody emicizumab “mimic[s] the function of FVIII by bringing together Factor IXa and Factor X,” illustrating the centrality of FIXa–FX complex assembly for effective intrinsic tenase activity (quote from review summarizing non‑factor approaches) (linari2025hemophiliachangesand pages 4-5), and perioperative guidance reiterates emicizumab “bridging activated factor IX and factor X” (quote) (lowell2024perioperativemanagementof pages 4-5). Large F9 deletions are associated with high inhibitor risk and allergic reactions in HB; these risks are highlighted clinically in infants presenting with severe bleeding such as intracranial hemorrhage (ICH) (lassandro2024intracranialhemorrhagein pages 1-2, wroblewska2025genetherapyas pages 1-2).

Key concepts and definitions (current understanding) - Etiology: Pathogenic F9 variants (missense, nonsense, splice, indels, large deletions/duplications) reduce FIX antigen/activity; X‑linked inheritance (wroblewska2025genetherapyas pages 1-2, baniamer2024understandinginheritedbleeding pages 2-4). - Severity thresholds: Severe <1% FIX activity; moderate 1–5%; mild 5–40% (baniamer2024understandinginheritedbleeding pages 2-4, wroblewska2025genetherapyas pages 1-2). - Core mechanism: Impaired intrinsic tenase (FVIIIa–FIXa) assembly/activity results in deficient propagation of thrombin generation and unstable fibrin formation (supported by emicizumab mechanism mimicking FVIII cofactor to bring FIXa and FX together) (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5). - Clinical manifestations: Spontaneous/joint bleeds in severe disease; post‑trauma/procedural bleeding in mild/moderate; ICH can be an initial presentation in infancy (baniamer2024understandinginheritedbleeding pages 2-4, lassandro2024intracranialhemorrhagein pages 1-2).

Recent developments and latest research (priority 2023–2024) AAV gene therapy (adult severe–moderately severe HB) - Fidanacogene elaparvovec (AAV) Phase 3 (BENEGENE‑2; NEJM 2024): annualized bleeding rate (ABR) decreased by 71% (from 4.42 to 1.28) 12–15 months post‑infusion vs prophylaxis lead‑in; mean FIX activity 26.9% at 15 months (median 22.9%; one‑stage SynthASil); 62% received glucocorticoids for transaminitis or decreased FIX; no thrombotic events or inhibitors (data‑cutoff Aug 30, 2023) (URL: https://doi.org/10.1056/NEJMoa2302982; published Sep 2024) (cuker2024genetherapywith pages 11-11). - Cross‑program summaries (2023–2024) report sustained FIX expression with mean values in the mid‑20s to mid‑30s percent and large reductions in bleeding and factor use (e.g., median ABR 12→0; FIX infusions 53.5→0), alongside frequent but manageable ALT elevations and steroid use; anti‑AAV neutralizing antibodies exclude many candidates (chernyi2024recentadvancesin pages 17-18). - Lancet 2025 review emphasizes real‑world considerations: pre‑existing AAV antibodies in ~25–40%, immune transaminase elevations requiring corticosteroids (weeks to months), variable durability, exclusion of children/inhibitor patients, and long‑term integration risk monitoring, while confirming multi‑year expression and cessation of prophylaxis for most recipients (URL: https://doi.org/10.1016/S0140-6736(24)02139-1; Mar 2025) (chowdary2025haemophilia pages 10-11).

Rebalancing (non‑factor) therapies (2023–2024 evidence base) - Anti‑TFPI monoclonal antibodies (concizumab, marstacimab): Mechanism restores initiation pathway by relieving TFPI inhibition to enhance FXa/thrombin generation. Phase 3 programs progressed; concizumab experienced thrombotic events (associated with concomitant hemostatic therapies) prompting protocol adjustments; marstacimab showed efficacy with superiority signals vs prior factor prophylaxis in patients without inhibitors (Lancet 2025 review) (chowdary2025haemophilia pages 9-10). A 2024 Cochrane review confirms the development status and comparative intent versus standard care (search last updated Aug 16, 2023) (). - Antithrombin siRNA (fitusiran): Monthly subcutaneous dosing lowers hepatic antithrombin mRNA to rebalance thrombin generation. Phase 3 data show significant ABR reductions but safety signals (thrombosis when antithrombin levels too low and when high‑dose concomitant hemostatics used; some hepatobiliary AEs). Risk‑mitigation includes antithrombin targets of ~15–35% and careful management of on‑demand agents (chowdary2025haemophilia pages 9-10). Perioperative guidance highlights a prior program hold after a fatal sinus thrombosis with concurrent high‑dose FVIII and notes reversibility with antithrombin supplementation (lowell2024perioperativemanagementof pages 4-5).

Extended half‑life (EHL) FIX products and inhibitor risk - EHL rFIXFc and rIX‑FP reduce infusion frequency and improve adherence; in pediatrics, weekly rFIXFc prophylaxis is feasible. Inhibitor formation and allergic reactions can occur, with large F9 deletions conferring elevated risk and potential nephrotic syndrome; a 2024 case demonstrates continued rFIXFc prophylaxis with pre‑medication after low‑titer inhibitor emergence, avoiding nephrotic progression (URL: https://doi.org/10.1186/s13052-024-01819-2; Nov 2024) (lassandro2024intracranialhemorrhagein pages 1-2). Reviews also reinforce that immune tolerance induction is less effective in HB inhibitor patients and that anaphylaxis/nephrotic syndrome risks are higher than in HA (wroblewska2025genetherapyas pages 1-2).

Current applications and real‑world implementations - Standard prophylaxis: Regular FIX replacement per severity is the global standard; even modest increases in factor activity can improve phenotype and reduce bleeds; humanitarian programs expand access (baniamer2024understandinginheritedbleeding pages 2-4). - Gene therapy: One‑time IV AAV delivery enabling cessation of routine prophylaxis in many adults; real‑world implementation requires screening for AAV antibodies, liver monitoring, steroid management, and long‑term follow‑up (cuker2024genetherapywith pages 11-11, chowdary2025haemophilia pages 10-11). - Non‑factor therapies: Emicizumab widely adopted for HA; in HB, rebalancing approaches (concizumab, marstacimab, fitusiran) are in late development or approved in some regions, with careful risk mitigation and guidance evolving (chowdary2025haemophilia pages 9-10, lowell2024perioperativemanagementof pages 4-5, linari2025hemophiliachangesand pages 4-5). - Perioperative management: Emicizumab interferes with aPTT‑based assays; use appropriate chromogenic or viscoelastic assays; avoid or limit aPCC due to thrombotic/TMA risks; rFVIIa preferred if needed (lowell2024perioperativemanagementof pages 4-5).

Expert opinions and authoritative analyses - Lancet 2025 review (international experts) synthesizes gene therapy implementation challenges (antibody exclusion, transaminitis, durability), and non‑factor therapy risk–benefit considerations; underscores individualized selection and registry data needs (chowdary2025haemophilia pages 10-11). - Perioperative experts highlight assay interference and thrombosis risk management with non‑factor agents, recommending tailored perioperative plans and judicious use of bypassing agents (lowell2024perioperativemanagementof pages 4-5). - Cochrane 2024 review catalogs the evidence base and uncertainties around non‑factor prophylaxis in congenital hemophilia ().

Relevant statistics and data from recent studies - Prevalence: ~1 in 30,000 males; severity thresholds severe <1%, moderate 1–5%, mild 5–40% FIX (baniamer2024understandinginheritedbleeding pages 2-4). - AAV gene therapy (fidanacogene elaparvovec, NEJM 2024): ABR −71% vs lead‑in; mean FIX 26.9% at 15 months; 62% on steroids for transaminase/FIX declines; 0 inhibitors/thromboses in the report (cuker2024genetherapywith pages 11-11). - AAV programs meta‑summary (2023–2024): FIX levels often mid‑20s to mid‑30s percent; high proportions without bleeding and cessation of factor use; ALT elevations common; anti‑AAV antibodies exclude many candidates (chernyi2024recentadvancesin pages 17-18). - Pediatric severe HB ICH case (2024): severe FIX deficiency (<1%) due to large F9 deletions; low‑titer inhibitor (0.6–1.0 BU) after EHL rFIXFc; premedication immunotolerance allowed continued weekly prophylaxis without nephrotic syndrome (lassandro2024intracranialhemorrhagein pages 1-2).

Molecular and cellular mechanisms - Molecular pathways dysregulated: intrinsic pathway propagation (defective FVIIIa–FIXa tenase assembly and function) leading to insufficient thrombin burst; rebalancing strategies target endogenous anticoagulants (TFPI, antithrombin) to restore thrombin generation (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5, chowdary2025haemophilia pages 9-10). - Cellular processes affected: Hepatocyte synthesis of FIX (secreted plasma zymogen); platelet‑surface and activated endothelium‑supported assembly of intrinsic tenase; impaired clot stability manifesting as clinical bleeding. Mechanistic surrogates from emicizumab’s action reinforce the requirement for colocalizing FIXa and FX (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5). - Tissues/organs: Liver (FIX synthesis), synovial joints and muscles (target bleeding sites), CNS (ICH risk in infants) (lassandro2024intracranialhemorrhagein pages 1-2, baniamer2024understandinginheritedbleeding pages 2-4).

Key molecular players - Genes/Proteins: F9 (HGNC:3551) encoding factor IX; interacting factors: FVIII (cofactor), FX, thrombin; endogenous anticoagulants targeted by non‑factor therapies: TFPI (anti‑TFPI mAbs), antithrombin (siRNA) (linari2025hemophiliachangesand pages 4-5, chowdary2025haemophilia pages 9-10, lowell2024perioperativemanagementof pages 4-5). - Chemical entities (CHEBI): - Anti‑TFPI monoclonal antibodies: concizumab, marstacimab (therapeutic biologics) (chowdary2025haemophilia pages 9-10). - siRNA: fitusiran (subcutaneous RNAi drug) (chowdary2025haemophilia pages 9-10, lowell2024perioperativemanagementof pages 4-5). - AAV gene therapy products: fidanacogene elaparvovec (AAV vector delivering FIX‑Padua) (cuker2024genetherapywith pages 11-11). - Cell types (CL): Hepatocytes (CL:0000182) – FIX production; platelets (CL:0000233) – tenase surface; endothelial cells (CL:0000115) – hemostatic interface. (Mechanistic context supported by emicizumab’s effect on bringing FIXa and FX together) (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5). - Anatomical locations (UBERON): Liver (UBERON:0002107); synovial joint (UBERON:0000982); brain/CNS (UBERON:0000955) (lassandro2024intracranialhemorrhagein pages 1-2, baniamer2024understandinginheritedbleeding pages 2-4).

Biological processes (GO) disrupted - Blood coagulation (GO:0007596) and intrinsic pathway of blood coagulation (GO:0007597): impaired FIX activation/function within intrinsic tenase (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5). - Regulation of thrombin generation (part of coagulation cascade): diminished in HB; therapeutically enhanced by anti‑TFPI and antithrombin‑lowering strategies (chowdary2025haemophilia pages 9-10, lowell2024perioperativemanagementof pages 4-5). - Response to wounding/hemostasis (GO:0009611/GO:0007599): abnormal bleeding phenotype (baniamer2024understandinginheritedbleeding pages 2-4).

Cellular components (GO) - Extracellular region/plasma (GO:0005576): circulating FIX zymogen. - Plasma membrane surfaces (platelets/endothelium) for intrinsic tenase assembly (protein complex at membrane) inferred from emicizumab’s bridging of FIXa and FX (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5).

Disease progression (sequence of events) 1) F9 pathogenic variant → reduced/absent functional FIX antigen/activity (wroblewska2025genetherapyas pages 1-2, baniamer2024understandinginheritedbleeding pages 2-4). 2) Impaired intrinsic tenase assembly/activity (FVIIIa–FIXa–phospholipid–Ca2+) → reduced FX activation and thrombin burst (supported by emicizumab mechanism that rescues tenase-like function by colocalizing FIXa and FX) (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5). 3) Inadequate fibrin generation/stability → bleeding after minimal trauma; in severe disease, spontaneous hemarthroses/muscle bleeds; infants can present with ICH (baniamer2024understandinginheritedbleeding pages 2-4, lassandro2024intracranialhemorrhagein pages 1-2). 4) Treatment modifies trajectory: EHL FIX increases trough levels; gene therapy can restore FIX into mild range; rebalancing therapies elevate thrombin potential but require thrombosis risk management (cuker2024genetherapywith pages 11-11, chowdary2025haemophilia pages 9-10, lowell2024perioperativemanagementof pages 4-5).

Phenotypic manifestations with mechanistic links (HP terms) - Recurrent hemarthrosis (HP:0003257) and chronic arthropathy (HP:0001362): due to inadequate tenase‑mediated thrombin generation during joint microtrauma (baniamer2024understandinginheritedbleeding pages 2-4). - Easy bruising (HP:0000978), epistaxis (HP:0000421), post‑procedural hemorrhage (HP:0001892) (baniamer2024understandinginheritedbleeding pages 2-4). - Intracranial hemorrhage (HP:0002170) in infancy/severe deficiency (lassandro2024intracranialhemorrhagein pages 1-2). - Inhibitor formation (alloantibodies) with allergic reactions/nephrotic syndrome risk in HB, especially with large F9 deletions (HP:0025354; mechanistic: anti‑FIX neutralization; immune complex complications) (lassandro2024intracranialhemorrhagein pages 1-2, wroblewska2025genetherapyas pages 1-2).

Evidence items (PMIDs/DOIs, URLs, dates) - NEJM 2024 (BENEGENE‑2; fidanacogene elaparvovec): ABR −71%; FIX ~27% at 15 months; steroid use 62%; no inhibitors/thromboses. DOI: 10.1056/NEJMoa2302982. URL: https://doi.org/10.1056/NEJMoa2302982. Published Sep 2024 (cuker2024genetherapywith pages 11-11). - Biomolecules 2024 review: summarizes AAV HB programs (AMT‑061/etranacogene dezaparvovec and others) with sustained FIX levels (mid‑20s to mid‑30s %) and substantial ABR/infusion reductions; notes ALT elevations and AAV antibody exclusions. DOI: 10.3390/biom14070854. URL: https://doi.org/10.3390/biom14070854. Published Jul 2024 (chernyi2024recentadvancesin pages 17-18). - Lancet 2025 review: gene therapy implementation (eligibility, immune toxicity, durability) and non‑factor therapies (anti‑TFPI, fitusiran) with risk–benefit framing. DOI: 10.1016/S0140-6736(24)02139-1. URL: https://doi.org/10.1016/S0140-6736(24)02139-1. Published Mar 2025 (chowdary2025haemophilia pages 10-11). - Italian J Pediatr 2024 case: infant ICH; rFIXFc prophylaxis, low‑titer inhibitor, immunotolerance premedication avoided nephrotic syndrome. DOI: 10.1186/s13052-024-01819-2. URL: https://doi.org/10.1186/s13052-024-01819-2. Published Nov 2024 (lassandro2024intracranialhemorrhagein pages 1-2). - Journal of Applied Genetics 2025 review: HB genetics (F9, Xq27.1), severity thresholds, EHL FIX, gene therapy approval context, inhibitor risks. DOI: 10.1007/s13353-025-00952-w. URL: https://doi.org/10.1007/s13353-025-00952-w. Published Apr 2025 (wroblewska2025genetherapyas pages 1-2). - Journal of Hematology & Oncology Research 2024 review: prevalence (~1/30,000 males), severity thresholds, standard prophylaxis rationale. DOI: 10.14302/issn.2372-6601.jhor-24-5108. URL: https://doi.org/10.14302/issn.2372-6601.jhor-24-5108. Published Aug 2024 (baniamer2024understandinginheritedbleeding pages 2-4). - Current Anesthesiology Reports 2024: perioperative management, emicizumab assay interference, aPCC thrombosis/TMA risks, rFVIIa preference; fitusiran program hold after fatal sinus thrombosis with high‑dose FVIII, reversibility with AT. DOI: 10.1007/s40140-024-00635-y. URL: https://doi.org/10.1007/s40140-024-00635-y. Published Jun 2024 (lowell2024perioperativemanagementof pages 4-5). - Cochrane Database of Systematic Reviews 2024: non‑factor therapies for congenital hemophilia A/B (concizumab, marstacimab, fitusiran) (search through Aug 16, 2023). DOI: 10.1002/14651858.CD014544.pub2. URL: https://doi.org/10.1002/14651858.CD014544.pub2. Published Feb 2024 (). - Frontiers in Medicine 2025 narrative review: HB mutation spectrum; intrinsic pathway pathophysiology; EHL, gene therapy, non‑factor strategies; global access issues. DOI: 10.3389/fmed.2025.1618464. URL: https://doi.org/10.3389/fmed.2025.1618464. Published Sep 2025 (dushimova2025therapeuticadvancesin pages 2-3).

Ontology‑style annotations - Gene/protein (HGNC): F9 (HGNC:3551) → Factor IX (serine protease zymogen) (wroblewska2025genetherapyas pages 1-2). - GO Biological Processes: blood coagulation (GO:0007596); intrinsic pathway of blood coagulation (GO:0007597); regulation of thrombin generation (supported by non‑factor strategies) (linari2025hemophiliachangesand pages 4-5, chowdary2025haemophilia pages 9-10, lowell2024perioperativemanagementof pages 4-5). - GO Cellular Components: extracellular region (GO:0005576); membrane‑bound tenase at activated platelet/endothelial surfaces (supported mechanistically by emicizumab bridging FIXa and FX) (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5). - Phenotype (HP): hemarthrosis (HP:0003257), arthropathy (HP:0001362), epistaxis (HP:0000421), easy bruising (HP:0000978), post‑procedural bleeding (HP:0001892), intracranial hemorrhage (HP:0002170), inhibitor formation (HP:0025354) (baniamer2024understandinginheritedbleeding pages 2-4, lassandro2024intracranialhemorrhagein pages 1-2, wroblewska2025genetherapyas pages 1-2). - Cell types (CL): hepatocytes (CL:0000182), platelets (CL:0000233), endothelial cells (CL:0000115) (mechanistic support via tenase/emicizumab bridging) (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5). - Anatomical locations (UBERON): liver (UBERON:0002107), synovial joint (UBERON:0000982), brain/CNS (UBERON:0000955) (lassandro2024intracranialhemorrhagein pages 1-2, baniamer2024understandinginheritedbleeding pages 2-4).

Direct quotes (selected) - “mimic the function of FVIII by bringing together Factor IXa and Factor X” (emicizumab mechanism) (linari2025hemophiliachangesand pages 4-5). - Emicizumab acts by “bridging activated factor IX and factor X,” with perioperative cautions on assay interference and thrombotic risk management (lowell2024perioperativemanagementof pages 4-5).

Plan status update - Core mechanisms, recent developments (2023–2024), applications, expert analyses, and statistics compiled from recent high‑quality sources (NEJM 2024; Cochrane 2024; perioperative review 2024; Lancet 2025 synthesis) and clinically relevant case evidence (ICH in infant) (cuker2024genetherapywith pages 11-11, lowell2024perioperativemanagementof pages 4-5, chowdary2025haemophilia pages 10-11, lassandro2024intracranialhemorrhagein pages 1-2).

Citations: (baniamer2024understandinginheritedbleeding pages 2-4, cuker2024genetherapywith pages 11-11, lassandro2024intracranialhemorrhagein pages 1-2, chernyi2024recentadvancesin pages 17-18, chowdary2025haemophilia pages 10-11, wroblewska2025genetherapyas pages 1-2, dushimova2025therapeuticadvancesin pages 2-3, chowdary2025haemophilia pages 9-10, lowell2024perioperativemanagementof pages 4-5, linari2025hemophiliachangesand pages 4-5)

References

1. (baniamer2024understandinginheritedbleeding pages 2-4): Ansam Zakaria Baniamer, Aya Mohannad Hamdan, Mohammad Raed AlGhzawi, Mohammad Tareq Alfaqeh, Sadeen Yaser Yaseen, Shama Mohammad Alshtawi, Hala Yasin Alomush, and Rand Mahdi Olimat. Understanding inherited bleeding disorders: genetic mutations in blood coagulation factors and regulatory proteins. Journal of Hematology and Oncology Research, 4:1-23, Aug 2024. URL: https://doi.org/10.14302/issn.2372-6601.jhor-24-5108, doi:10.14302/issn.2372-6601.jhor-24-5108. This article has 2 citations.

2. (linari2025hemophiliachangesand pages 4-5): Silvia Linari and Giancarlo Castaman. Hemophilia: changes and new achievements in management and care. International Journal of Bone Fragility, 5:66-71, Oct 2025. URL: https://doi.org/10.57582/ijbf.250502.066, doi:10.57582/ijbf.250502.066. This article has 0 citations.

3. (lowell2024perioperativemanagementof pages 4-5): Aliena E. Lowell, Michael P. Calgi, Joseph J. Caruso, Louise M. Man, and John S. McNeil. Perioperative management of hemophilia patients. Current Anesthesiology Reports, 14:354-365, Jun 2024. URL: https://doi.org/10.1007/s40140-024-00635-y, doi:10.1007/s40140-024-00635-y. This article has 7 citations and is from a peer-reviewed journal.

4. (lassandro2024intracranialhemorrhagein pages 1-2): Giuseppe Lassandro, Valentina Palladino, and Paola Giordano. Intracranial hemorrhage in an infant leads to the diagnosis and treatment of severe hemophilia b: a case report. Italian Journal of Pediatrics, Nov 2024. URL: https://doi.org/10.1186/s13052-024-01819-2, doi:10.1186/s13052-024-01819-2. This article has 0 citations and is from a peer-reviewed journal.

5. (wroblewska2025genetherapyas pages 1-2): Kinga Wróblewska, Dominika Bieszczad, Magdalena Popławska, Karolina Joanna Ziętara, Monika Zajączkowska, and Agata Filip. Gene therapy as an innovative approach to the treatment of hemophilia b-a review. Journal of applied genetics, Apr 2025. URL: https://doi.org/10.1007/s13353-025-00952-w, doi:10.1007/s13353-025-00952-w. This article has 0 citations and is from a peer-reviewed journal.

6. (cuker2024genetherapywith pages 11-11): Adam Cuker, Kaan Kavakli, Laurent Frenzel, Jiaan-Der Wang, Jan Astermark, Monica H. Cerqueira, Alfonso Iorio, Olga Katsarou-Fasouli, Robert Klamroth, Amy D. Shapiro, Cédric Hermans, Akira Ishiguro, Andrew D. Leavitt, Johannes B. Oldenburg, Margareth C. Ozelo, Jerome Teitel, Francesca Biondo, Annie Fang, Joanne Fuiman, John McKay, Pengling Sun, John E.J. Rasko, and Jeremy Rupon. Gene therapy with fidanacogene elaparvovec in adults with hemophilia b. The New England journal of medicine, 391 12:1108-1118, Sep 2024. URL: https://doi.org/10.1056/nejmoa2302982, doi:10.1056/nejmoa2302982. This article has 74 citations and is from a highest quality peer-reviewed journal.

7. (chernyi2024recentadvancesin pages 17-18): Nikita Chernyi, Darina Gavrilova, Mane Saruhanyan, Ezekiel S. Oloruntimehin, Alexander Karabelsky, Evgeny Bezsonov, and Alexander Malogolovkin. Recent advances in gene therapy for hemophilia: projecting the perspectives. Biomolecules, 14:854, Jul 2024. URL: https://doi.org/10.3390/biom14070854, doi:10.3390/biom14070854. This article has 33 citations and is from a poor quality or predatory journal.

8. (chowdary2025haemophilia pages 10-11): Pratima Chowdary, Manuel Carcao, Gili Kenet, and Steven W Pipe. Haemophilia. The Lancet, 405:736-750, Mar 2025. URL: https://doi.org/10.1016/s0140-6736(24)02139-1, doi:10.1016/s0140-6736(24)02139-1. This article has 33 citations and is from a highest quality peer-reviewed journal.

9. (chowdary2025haemophilia pages 9-10): Pratima Chowdary, Manuel Carcao, Gili Kenet, and Steven W Pipe. Haemophilia. The Lancet, 405:736-750, Mar 2025. URL: https://doi.org/10.1016/s0140-6736(24)02139-1, doi:10.1016/s0140-6736(24)02139-1. This article has 33 citations and is from a highest quality peer-reviewed journal.

10. (dushimova2025therapeuticadvancesin pages 2-3): Zaure Dushimova, Marat Pashimov, Jamilya Kaibullayeva, Laura Danyarova, Elmira Kultanova, Gulnara Abdilova, and Nagima Mustapayeva. Therapeutic advances in hemophilia: from molecular innovation to patient-centered global care. Frontiers in Medicine, Sep 2025. URL: https://doi.org/10.3389/fmed.2025.1618464, doi:10.3389/fmed.2025.1618464. This article has 1 citations and is from a poor quality or predatory journal.

The Pathophysiology of Hemophilia B: Molecular Mechanisms, Cellular Dysfunction, and Clinical Manifestations

This comprehensive report examines the molecular and cellular pathophysiology of hemophilia B, a rare X-linked bleeding disorder resulting from deficiency or dysfunction of coagulation factor IX. Hemophilia B, also known as Christmas disease, represents a critical derangement in the intrinsic blood coagulation pathway stemming from mutations in the F9 gene located on the X chromosome at band Xq27.1[13]. The disease presents with profound heterogeneity in clinical severity, ranging from asymptomatic carrier females to males experiencing spontaneous life-threatening hemorrhages. At the molecular level, hemophilia B pathophysiology revolves around inadequate production or function of Factor IX (FIX), a vitamin K-dependent serine protease essential for initiating and amplifying thrombin generation through formation of the intrinsic tenase complex[8][13]. This report integrates current understanding of the F9 gene structure and mutation landscape, the biochemical properties and post-translational modifications of the FIX protein, the disruption of coagulation cascade dynamics, and the progression from genetic defect to symptomatic bleeding manifestations. The mechanistic framework presented here provides critical insights into disease severity predictors, complications including arthropathy and inhibitor formation, and emerging therapeutic strategies targeting the dysregulated coagulation system.

Molecular Genetics and the F9 Gene: Structural Organization and Mutation Landscape

F9 Gene Structure and Organization

The F9 gene, encoding coagulation factor IX, spans approximately 34 kilobases on the X chromosome and comprises eight exons separated by seven introns[13][3]. This structural organization is critical for understanding how mutations at different genomic loci produce variable clinical phenotypes in hemophilia B. Exon 1 encodes the signal peptide, a 28-residue sequence that directs the nascent protein into the endoplasmic reticulum (ER) during synthesis[13]. Exon 2 encodes both the propeptide, an 18-residue sequence essential for recognition by the vitamin K-dependent γ-glutamyl carboxylase, and the beginning of the γ-carboxyglutamic acid (Gla) domain[13]. Exons 3 through 8 collectively encode the remaining structural and functional domains of the mature FIX protein, including the epidermal growth factor-like (EGF) domains, the activation peptide, and the serine protease catalytic domain[3][13].

The 2.8-kilobase mRNA transcript produced from the F9 gene is translated into a 461-amino acid preproprotein (prepro-FIX) that undergoes extensive post-translational processing[1][3]. This preproprotein contains several distinct functional regions: the 28-residue signal peptide, the 18-residue propeptide that facilitates vitamin K-dependent γ-carboxylation, and the mature 415-amino acid FIX protein consisting of the Gla domain (amino acids 1-40), a short hydrophobic sequence (aa 41-46), two EGF-like domains (EGF-1: aa 47-83; EGF-2: aa 88-125), a linker region (aa 126-145), an activation peptide (aa 146-180), and the C-terminal serine protease domain (aa 181-415)[13]. The functional significance of this organization becomes apparent when examining how mutations in specific exons and regulatory regions produce disease manifestations of varying severity[1][3].

Mutation Types and Distribution in Hemophilia B

The F9 locus-specific mutation database (F9db) documents more than 3,000 pathogenic mutations and neutral polymorphisms affecting 73 percent of the 461 residues in the mature FIX protein[1]. Point mutations account for the vast majority of hemophilia B cases, with these mutations generally categorized into missense mutations (causing changes in amino acids), nonsense mutations (creating premature stop codons), frameshift mutations (insertions or deletions causing translational errors), and splice-site mutations affecting mRNA processing[1][3]. The distribution of these mutation types varies across different structural domains of FIX. Frameshift and nonsense mutations are relatively evenly distributed throughout the FIX protein, which is expected given that these types of mutations produce truncated or defective proteins regardless of their location[3]. Missense mutations, however, show a characteristic distribution pattern, being present in all protein domains except the middle region of the activation peptide, with notable underrepresentation in the signal peptide and activation domains because these regions tolerate amino acid changes with less functional consequence[3].

The protease domain contains the majority of documented mutations overall, reflecting both its large size and the critical functional importance of the serine protease active site for FIX enzymatic activity[3]. Large deletion and insertion mutations, though less common than point mutations in hemophilia B compared to hemophilia A, still contribute significantly to disease pathogenesis[4]. Complex mutations including large deletions from multiple exons, such as a documented 4.4 kilobase deletion spanning exons 4-6 with replacement by a 47-base pair sequence, and insertions of mobile genetic elements including Alu elements into exon 5 and long interspersed nuclear elements into exon 7, have been identified in hemophilia B patients[1]. These complex rearrangements typically produce severe phenotypes due to disruption of multiple protein domains[1].

Deep intronic mutations representing variants located far from exon-intron boundaries are rarely reported in hemophilia B, though such mutations have been documented in other bleeding disorders[1]. The paucity of reported deep intronic mutations in hemophilia B likely reflects the historical limitation that standard mutation detection techniques using PCR and Sanger sequencing have not routinely sought these variants[1]. As next-generation sequencing technologies become more widely implemented, additional deep intronic mutations causing hemophilia B through mechanisms such as cryptic splicing will likely be identified. Mutation analysis using PCR and Sanger sequencing combined with dosage analysis for detecting large deletions and duplications enables detection of mutations in more than 97 percent of hemophilia B patients[1].

Promoter Mutations and Hemophilia B Leyden: Variable Phenotypes Linked to Gene Regulation

A distinctive category of F9 mutations affects the proximal promoter region of the F9 gene, producing a unique phenotype known as hemophilia B Leyden in which disease severity dramatically improves following puberty[1][3]. The proximal promoter contains binding sites for multiple transcription factors essential for constitutive FIX expression[1]. A short region spanning from position -50 to -18 relative to the transcription start site contains three critical transcription factor binding sites: hepatic nuclear factor 4α (HNF4α) binding at position -49, CCAAT enhancer-binding protein binding at position -19, and ONECUT1 and ONECUT2 binding centered around position -35[1]. Point mutations within these regulatory sequences, including well-characterized mutations such as c.-49T>A and c.-50T>G, disrupt transcription factor binding during infancy and childhood but paradoxically allow restoration of FIX expression following puberty[3]. The mechanism underlying this remarkable improvement involves androgen-responsive elements that become activated during the pubertal surge in androgen levels, which can drive FIX transcription through alternative regulatory pathways[1][3].

Patients with hemophilia B Leyden represent approximately 5 percent of hemophilia B cases and present with severe factor IX deficiency in childhood with plasma FIX levels less than 1 percent[3]. However, following puberty, FIX levels progressively increase, often rising to 50-70 percent of normal activity in adulthood[3]. This unique disease course, while rare, provides valuable insights into the regulation of hepatic FIX expression and demonstrates that some hemophilia B mutations do not produce immutable defects but rather condition gene expression patterns that respond to developmental and hormonal cues. Mutations in the 3' untranslated region (3'UTR) of the F9 gene, though identified, have not been associated with severe hemophilia B phenotypes, suggesting that regulatory elements outside the promoter region have limited impact on overall FIX expression levels[3].

Biochemical Properties of Factor IX: Structure-Function Relationships and Post-Translational Modifications

The Gla Domain: Calcium-Dependent Membrane Binding and Its Role in Hemostasis

Factor IX, like other vitamin K-dependent coagulation factors including prothrombin, factor VII, factor X, protein C, and protein S, contains a distinctive N-terminal γ-carboxyglutamic acid (Gla) domain comprising residues 1-40 of the mature protein[13]. This domain contains twelve γ-carboxylated glutamic acid (Gla) residues, with the first eleven being highly conserved across species and critically important for FIX function, while the twelfth residue appears to have minimal functional significance[13]. The Gla domain structure consists of an N-terminal loop and three short β-sheets arranged in a characteristic disulfide-bonded framework that is stabilized by calcium ion binding[13][14]. The structural basis for calcium-dependent function of the Gla domain involves a sophisticated ion coordination mechanism in which four calcium ions (Ca2+ through Ca5+) are essential to stabilize the Gla domain conformation and expose critical binding surfaces[13][14].

Upon calcium binding to FIX, a conformational change occurs in the Gla domain through clustering of N-terminal hydrophobic residues into a hydrophobic patch that becomes exposed to the solvent[14]. This hydrophobic patch subsequently allows association of the Gla domain with cell surface membranes through electrostatic interactions between the negatively charged phosphoserine head groups of phosphatidylserine in the membrane and positively charged arginine and lysine residues in the Gla domain[14]. The basic amino acid residues Lys5 and Arg10 specifically bind to the glycerol phosphate backbone of phospholipids, while the carboxyl group of the serine residue interacts with Ca5+ and Ca6+, allowing membrane association[14]. This calcium-dependent membrane binding mechanism is absolutely essential for FIX function; in the absence of adequate calcium concentration, the Gla domain becomes highly disordered and unstructured, preventing membrane association and consequently blocking FIX participation in the coagulation cascade[14].

Magnesium ions may also play a modulatory role in Gla domain function distinct from calcium's structural role. Crystallographic studies of bovine FIX bound to a snake venom protein reveal that magnesium ions induce a closed-form conformation of the Gla domain that contributes to tight association with phospholipid membranes[14]. The Mg2+ ion coordination differs from O-Ca-O bridges observed with calcium, potentially contributing differential effects on membrane binding affinity and orientation[14]. Additionally, magnesium ions in the Gla domain may contribute to binding interactions with cofactors including factor VIIIa and factor VIIa[14].

The Epidermal Growth Factor-Like Domains: Enabling Protein-Protein Interactions

Following the Gla domain and a short hydrophobic sequence, the FIX protein contains two epidermal growth factor-like (EGF) domains that serve primarily structural roles by enabling spatial separation between the serine protease domain and phospholipid membranes[13]. This spatial organization is critical because FIXa must bind both FX and the cofactor FVIIIa, which are also membrane-bound, and the EGF domains provide the necessary distance for these protein-protein interactions to occur on the membrane surface[13]. The EGF-1 domain (amino acids 47-83) and EGF-2 domain (amino acids 88-125) both contain disulfide-bonded structures essential for maintaining proper three-dimensional conformation[13].

Biochemical and molecular modeling studies demonstrate that the EGF domains mediate essential protein-protein interactions beyond simple spatial positioning[13]. The EGF-1 domain appears to mediate binding to the tissue factor-FVIIa complex, with the glycine at position 48 playing an essential role in FIX activation by the extrinsic coagulation pathway[13]. Furthermore, both EGF domains contribute to binding interactions with FVIIIa, the critical cofactor that dramatically enhances the catalytic activity of FIXa in the intrinsic tenase complex[13]. The EGF-2 domain is connected to the serine protease catalytic domain through a disulfide bridge and is positioned opposite the catalytic active site[14]. This structural arrangement positions the EGF-2 domain to potentially interact with substrate molecules approaching the active site and to facilitate interactions with cofactors and membrane surfaces that position FIXa correctly for catalytic turnover[13].

The Activation Peptide: Cleavage Site for Zymogen Activation

The FIX protein circulates in plasma as an inactive zymogen and is converted to its enzymatically active form (FIXa) through proteolytic cleavage of the activation peptide (amino acids 146-180)[3][13]. This conversion occurs through sequential cleavage at two arginine residues: Arg191 (at the junction between the activation peptide and linker region) and Arg226 (within the activation peptide) by either activated FXI or the tissue factor-FVIIa complex[1][13]. The final residue of the linker region preceding the activation peptide, Arg145, serves as one of these two cleavage sites for activation by FXIa and the TF-FVIIa complex, while Arg180 located within the activation peptide represents the second cleavage site[13]. The removal of the 11 kilodalton activation peptide exposes the serine protease active site on the heavy chain, which can then activate Factor X in the presence of Factor VIII, calcium, and phospholipid surfaces[14].

The significance of the activation peptide for FIX function becomes apparent when examining hemophilia B mutations occurring at the junctions between the activation domain and its adjacent domains, which suggest that mutations might interfere with normal cleavage processes and result in production of dysfunctional FIX proteins that cannot be properly activated[3]. Missense mutations found in the junction regions between the activation domain and EGF-2 domain are thought to impair the three-dimensional folding necessary for recognition by activating proteases[3].

The Serine Protease Domain: Catalytic Architecture and Functional Anatomy

The serine protease domain of FIX (amino acids 181-415) comprises the largest functional region of the mature protein and contains the catalytic machinery essential for FIX enzymatic activity[13][14]. This domain is structurally related to other serine proteases including trypsin and thrombin but exhibits much narrower substrate specificity, cleaving specifically at arginine-isoleucine bonds within factor X[8][13]. The catalytic domain consists of two β-subdomains that form an active site at their interface, with three disulfide bonds stabilizing the domain structure and helical structures running across the N-terminus of the β-barrel[14].

The active site of FIX contains a catalytic triad characteristic of trypsin-like serine proteases, composed of three amino acids: a histidine residue that acts as a general base, an aspartate residue that stabilizes the developing charge during catalysis, and a serine residue that performs the nucleophilic attack on substrate peptide bonds[14]. Unlike other serine protease family members, vitamin K-dependent proteases including FIX have an extended specificity pocket that allows recognition of a limited number of amino acids in the substrate sequence, contributing to the high substrate specificity of FIX for factor X[13]. The substrate specificity of FIXa is further refined by several ion-binding sites and exosite regions within the protease domain[13].

The protease domain contains multiple exosites—extended binding surfaces distinct from the catalytic active site—that contribute to substrate recognition and binding without directly participating in catalysis[13]. These exosites are primarily located in flexible loops and include features such as the 126-loop (the "126-c helix"), the 162-loop (the "162-c helix"), and the Asn178 residue[13]. The protease domain also contains important ion-binding sites: a single calcium ion binds in the exosite I region, while a sodium ion binds in the 186-220 region[13]. Exosite II is known to bind heparin and may also contribute additional binding surfaces for the cofactor FVIIIa[13]. A distinctive structural feature termed the "99-loop" (residues Glu219, Lys98, and Tyr177) partially obstructs the active site entrance and is thought to reduce the activity of FIXa compared to fully unobstructed serine proteases[13]. Interestingly, mutations in this 99-loop region have been experimentally used to increase FIXa enzymatic activity, demonstrating the mechanistic relationship between this structural feature and catalytic efficiency[13].

Vitamin K-Dependent γ-Carboxylation: Essential Post-Translational Modification

Vitamin K-dependent γ-carboxylation represents a critical post-translational modification essential for FIX function that occurs in the endoplasmic reticulum[13][49]. This modification converts specific glutamic acid residues in the Gla domain to γ-carboxyglutamic acid residues through an enzymatic reaction catalyzed by γ-glutamyl carboxylase (GGCX), which uses vitamin K as a cofactor[13][49]. Vitamin K-epoxide reductase then recycles vitamin K to its active reduced form, completing the catalytic cycle[13][49]. The carboxylation process is initiated by recognition of the FIX propeptide, an 18-amino acid sequence immediately following the signal peptide that functions as a recognition element for GGCX[13][49]. The conserved residues at positions -6 and -10 within the propeptide are essential for binding to GGCX and for achieving efficient substrate carboxylation[49].

The biological importance of γ-carboxylation becomes evident in clinical observations: hemophilia B patients carrying mutations at position -4 or -1 of the propeptide prevent post-translational cleavage of the propeptide, resulting in secretion of pro-coagulation factor with the propeptide still attached[49]. Such mutations either block or severely reduce the carboxylation efficiency of FIX, contributing to the bleeding phenotype observed in these patients[49]. The necessity of vitamin K as a cofactor for this modification explains the increased bleeding risk in individuals with vitamin K deficiency due to malabsorption or anticoagulation therapy with warfarin, which inhibits vitamin K-epoxide reductase and consequently impairs the carboxylation of all vitamin K-dependent coagulation factors[49].

Disruption of the Coagulation Cascade: The Intrinsic Pathway and Tenase Complex Formation

The Intrinsic Pathway and Factor IX's Role in Thrombin Amplification

The blood coagulation cascade represents a carefully orchestrated series of proteolytic reactions that culminate in thrombin generation and fibrin formation, enabling hemostasis through stabilization of the platelet plug[8][45]. The cascade is traditionally conceptualized as comprising separate extrinsic and intrinsic pathways that converge on a common pathway, though contemporary understanding emphasizes a more integrated tissue factor-initiated model in which the intrinsic pathway plays a critical amplification role[8][26][27][32]. The intrinsic pathway comprises coagulation factors XII, XI, IX, and VIII, which are all present in blood and can be activated by negatively charged surfaces in vitro[45]. However, physiological hemostasis depends critically on the intrinsic pathway through a mechanism distinct from contact activation; FXI activation by thrombin downstream of the extrinsic pathway, in conjunction with polyphosphates released from activated platelets, amplifies coagulation through FIX activation[26][27][32].

Factor IX occupies a pivotal position within the intrinsic pathway as the substrate for FXI-catalyzed activation and as a component of the intrinsic tenase complex[8][26]. Upon activation by either FXI or the tissue factor-FVIIa complex, FIX becomes activated (FIXa) and, in the presence of the cofactor FVIIIa, calcium ions, and phospholipid surfaces, forms the intrinsic tenase complex[8][45]. This complex exhibits extraordinary catalytic efficiency, activating factor X at a rate approximately 50-fold higher than the extrinsic tenase complex (tissue factor-FVIIa), thereby dramatically amplifying thrombin generation[8][27][32][45]. The intrinsic tenase complex catalyzes hydrolysis of the Arg194-Ile195 bond in the heavy chain of factor X, releasing a 52-residue activation peptide and generating factor Xa[32].

The intrinsic pathway's role in amplifying coagulation is particularly significant at specific anatomical sites with low expression of tissue factor. Individuals with hemophilia A or B are uniquely prone to hemorrhages in joints and skeletal muscle, both sites with low levels of tissue factor expression[27]. This clinical observation strongly suggests that hemostasis in skeletal muscle and joints is more dependent on the intrinsic pathway rather than the extrinsic pathway, underscoring the critical physiological role of factor VIII and factor IX in these tissues[27].

Factor VIII as Essential Cofactor: The Mechanism of Intrinsic Tenase Complex Formation

The activation of FIXa is necessary but insufficient for hemostatic efficacy; FIXa requires the non-enzymatic cofactor FVIIIa to achieve hemostatic competence[8][27]. Activated factor VIII circulates as a heterotrimer following its release from von Willebrand factor and proteolytic activation by thrombin, consisting of the A1 and A2 domains plus the FVIIIa light chain (A3-C1-C2)[44]. The light chain domains of FVIIIa, particularly the C1 and C2 domains, mediate binding to phospholipid membranes and contribute to cofactor interactions with FIXa[47][44]. FVIIIa binds to FIXa on anionic membranes to form the intrinsic Xase enzyme complex responsible for activating FX in the rate-limiting step of sustained coagulation[44].

The activation of FIXa is accompanied by a conformational change that exposes the FIX binding site on FVIIIa and positions FIXa correctly relative to the substrate factor X on the membrane surface[14]. The Gla domain of FIX likely promotes FVIIIa binding to phospholipid membranes through its calcium-dependent conformational changes, and the arched structure formed by membrane-bound FIXa creates a concave surface that acts as a binding site for factor VIIIa[14]. The cooperative assembly of the intrinsic tenase complex on phospholipid membrane surfaces—particularly the phosphatidylserine-containing membranes of activated platelets—represents a critical regulatory mechanism ensuring that thrombin amplification occurs only at sites of vascular injury[8][27][45].

The Role of Factor X Activation in Prothrombinase Complex Formation and Thrombin Burst

Following activation of factor X to factor Xa by the intrinsic tenase complex, factor Xa proceeds through the common pathway of coagulation[32][35]. Factor Xa, in the presence of calcium ions and with the protein cofactor factor Va on phospholipid membranes, forms the prothrombinase complex, which catalyzes the conversion of prothrombin (factor II) to thrombin (factor IIa)[32][35][45]. This prothrombinase complex represents the most catalytically efficient step in coagulation, with factor Xa activating prothrombin at a rate approximately 300,000-fold faster than factor Xa alone[32]. The formation of the prothrombinase complex is optimized when factor Xa is complexed with its cofactor factor Va, which reduces the Km for prothrombin substrate while increasing the Vmax of the reaction[32].

The catalytic mechanism of thrombin generation warrants careful attention because it illuminates how even minor deficiencies in intrinsic pathway function can profoundly impair hemostasis. Factor Xa catalyzes activation of prothrombin through hydrolysis of two peptide bonds; one pathway, considered most physiologically relevant, involves cleavage of the Arg320-Ile321 bond to yield an intermediate molecule called meizothrombin, which may then be cleaved at the Arg271-Thr272 bond to yield fragment 1-2 and fully activated thrombin[32]. The resultant thrombin, although initially generated in small amounts from the extrinsic pathway, serves as a potent amplifier of coagulation through multiple positive feedback mechanisms. Thrombin activates cofactors FV and FVIII, promoting increased assembly of prothrombinase and intrinsic tenase complexes, and also activates factor XI, which feeds back to activate additional factor IX[8][32][45].

The concept of "thrombin burst" describes the exponential amplification of thrombin generation that occurs once sufficient quantities of cofactors are activated and membrane surfaces are primed with activated platelets[8][32]. In normal hemostasis, the generation of even small initial amounts of thrombin from the extrinsic pathway sets off this amplification cascade, culminating in massive thrombin generation and comprehensive fibrin formation[8][32]. In hemophilia B, the deficiency of factor IX fundamentally impairs this amplification step: FIXa cannot be formed in adequate quantities, the intrinsic tenase complex cannot be properly assembled, and consequently factor X activation through the intrinsic pathway is severely diminished[8].

Pathophysiology of Hemophilia B: From Genetic Defect to Impaired Hemostasis

Molecular Mechanisms of Factor Deficiency and Dysfunction

Hemophilia B results from several different molecular mechanisms, each producing inadequate levels or dysfunctional forms of factor IX[1]. The primary categories of molecular pathophysiology include: complete absence of FIX protein (null mutations), reduced synthesis of normal-appearing FIX (missense mutations affecting secretion or stability), synthesis of structurally normal FIX with reduced specific activity (missense mutations affecting catalytic sites), and production of FIX with abnormal post-translational modification (carboxylation or other processing defects)[1][3]. Large deletions and nonsense mutations typically produce severe hemophilia B through complete loss of FIX expression, as the truncated proteins are non-functional and often unstable[3]. Frameshift mutations similarly produce premature termination codons and nonfunctional proteins[3].

The relationship between mutation type and resulting FIX activity levels demonstrates clear patterns: mutations that prevent protein synthesis or produce truncated proteins correlate with severe phenotypes and approximately 5 percent risk of inhibitor development, while missense mutations generally produce milder or moderate phenotypes with lower inhibitor risk[1][3][4]. Approximately one-third of hemophilia B patients are classified as cross-reacting material positive (CRM), meaning they produce detectable antigen-positive FIX protein despite having reduced or absent enzymatic activity[4]. This higher prevalence of CRM-positive hemophilia B compared to hemophilia A is explained by the higher frequency of missense mutations in hemophilia B; missense mutations can produce structurally recognizable but functionally defective protein[4].

Some missense mutations in hemophilia B affect specific functional domains while leaving others intact. For example, mutations affecting the serine protease domain active site dramatically reduce catalytic efficiency but may not eliminate the protein's synthesis or secretion[3][13]. Mutations affecting the Gla domain or EGF domains may reduce membrane binding or protein-protein interaction capabilities without affecting the catalytic machinery[1][13]. Mutations affecting linker regions between domains may impair proper three-dimensional folding and zymogen activation[1][3].

Plasma Factor Activity Levels and Clinical Classification

The clinical severity of hemophilia B is classified into three categories based on plasma factor IX activity levels: normal plasma levels of FIX range from 50 to 150 percent, whereas patients with less than 1 percent of normal activity (less than 0.01 IU/ml) are classified as severe, those with 1-5 percent activity are classified as moderate, and those with 5-40 percent activity are classified as mild[1][3][5][10]. The inverse relationship between plasma FIX activity and bleeding tendency is robust and reproducible: as residual FIX activity decreases, the frequency and severity of spontaneous bleeding episodes increase[3][9][36]. However, this relationship is not perfectly linear, and substantial individual variation in bleeding phenotype exists even among patients with similar FIX activity levels[3][36].

In mild hemophilia B with factor activity between 5-40 percent, bleeding typically occurs only after significant trauma, surgery, or invasive dental procedures, and many patients may not be diagnosed until such an event requires medical attention[5][10]. Patients with moderate hemophilia B (1-5 percent activity) experience occasional spontaneous bleeding episodes, particularly into joints and muscles, and are at risk for prolonged bleeding following any surgical procedure or injury[10][55]. Severe hemophilia B with factor activity less than 1 percent presents with frequent spontaneous bleeding episodes affecting joints, muscles, and other tissues, and often manifests clinically in infancy with bleeds following circumcision, intramuscular vaccinations, or minor trauma associated with learning to walk[9][10][58].

An important caveat regarding the classification system warrants emphasis: plasma factor activity levels do not predict bleeding severity with absolute precision[3][29]. Some patients with moderately reduced FIX levels experience more frequent bleeding than would be predicted by their activity level, while others with very low levels may have fewer bleeds than expected[3][29]. This heterogeneity reflects the influence of additional genetic, acquired, and behavioral factors on bleeding phenotype, including the presence of prothrombotic genetic polymorphisms, the level and phenotype of von Willebrand factor, body mass index, and engagement in high-risk physical activities[3][4][36].

Clinical Manifestations: Linking Molecular Deficiency to Tissue-Specific Bleeding

Joint Hemorrhage and Hemophilic Arthropathy: The Primary Manifestation of Severe Hemophilia B

Hemarthrosis, bleeding into the joint cavity, represents the hallmark clinical manifestation of hemophilia B, accounting for nearly 80 percent of all hemorrhages in the disease[9][12][19][31][33]. The knees, elbows, and ankles are the most frequently affected joints, though bleeding can occur in shoulders, wrists, hips, and toes[9][12][31]. The pathophysiology of hemarthrosis in hemophilia B involves the inability to generate sufficient thrombin in response to vascular injury within the synovial space, resulting in continued bleeding into the joint until the plasma FIX level is raised through replacement therapy or the bleeding spontaneously ceases due to hemostatic mechanisms independent of FIX activity[9][12].

When blood accumulates within a joint space, the rising pressure causes acute pain through direct distension and activation of nociceptors[34]. Early signs of joint bleeding include stiffness, tingling or "aura" sensations within the joint, joint warmth, and swelling[12]. If left untreated, acute hemarthrosis progresses to severe pain, significant swelling, limited range of motion, and potential permanent joint damage[12][34]. The treatment of acute hemarthrosis requires prompt administration of sufficient factor IX concentrate to elevate plasma FIX levels to approximately 40-50 percent activity, with the goal of achieving hemostasis and halting the bleeding before permanent damage develops[12][34][60].

Recurrent hemarthrosis drives the development of hemophilic arthropathy, a chronic joint condition characterized by progressive cartilage and bone destruction[19][31][33][34]. The pathophysiology of hemophilic arthropathy involves complex interactions between the toxic effects of accumulated iron from red blood cell breakdown, inflammatory cascades triggered by the presence of blood in the joint space, and hemodynamic factors[19][31]. Hemosiderin, a complex iron-storage molecule formed when hemoglobin from red blood cells is broken down, accumulates in the synovium and can undergo the Fenton reaction with hydrogen peroxide to generate hydroxyl radicals—highly reactive molecules that cause oxidative damage to cellular structures[19][31]. The iron from hemoglobin catalyzes this Fenton reaction, producing reactive oxygen species that activate inflammatory pathways through mechanisms including activation of the nuclear factor kappa B (NF-κB) pathway[19][31]. This inflammatory activation triggers release of cytokines and proteolytic enzymes from synovial cells and infiltrating immune cells, leading to degradation of articular cartilage and damage to the subchondral bone[19][31][33].

Repeated bleeding into a joint leads to synovial hypertrophy and fibrosis, transforming the normally thin synovial membrane into chronically inflamed, thickened tissue[19][22][31][33]. The hypertrophied synovium becomes highly vascularized, with new vessel formation through angiogenesis[19][31][33]. These newly formed vessels are friable and prone to bleeding, creating a vicious cycle in which synovial hypertrophy and hypervascularization lead to further bleeding and continued inflammation[19][22][31][33]. This cycle of bleeding, iron accumulation, synovial proliferation, and hypervascularization perpetuates progressive joint damage[19][22][31][33].

Over time, the combination of cartilage erosion, subchondral cyst formation, and bone destruction results in hemophilic arthropathy with joint deformity, severe pain, and loss of function[19][31][34]. MRI imaging reveals that chronic effusions and changes to the joint capsule, coupled with inflammatory mediators, decrease proprioceptive ability in affected joints, further compromising joint stability and function[22]. The prevalence of chronic arthropathy affects approximately 20 percent of hemophiliacs and represents the single largest cause of morbidity in patients with hemophilia[34][33]. Early prophylaxis with factor replacement significantly reduces the development of arthropathy; studies demonstrate that children receiving prophylaxis achieve normal joint structure on MRI in 93 percent of cases at study endpoint compared to only 55 percent in patients receiving episodic treatment[19][22].

Muscle and Deep Tissue Hemorrhage: Pseudotumors and Compartment Syndrome

Muscle hematomas represent another major category of hemophilia B bleeding manifestations, accounting for 10-25 percent of all bleeds in severe hemophilia[39]. Iliopsoas muscle bleeding is the most common site of muscle hemorrhage, occurring in approximately 55 percent of muscle bleed cases[39]. These bleeds represent a clinical emergency because the large capacity of deep muscle compartments allows massive blood accumulation before external signs become apparent, creating risk for severe anemia, hypovolemic shock, and nerve compression[9][39][60]. A bleeding episode into the iliopsoas muscle presents with pain and flexion deformity of the hip, difficulty extending the hip, and potential signs of femoral nerve compression including weakness or numbness in the leg[9][39][60].

If muscle hemorrhage is not adequately treated, the accumulated blood becomes organized and fibrous, creating a structure known as a hemophilic pseudotumor—a firm, encapsulated mass of clotted blood and necrotic tissue[39]. Hemophilic pseudotumors, while rare, represent devastating complications that can cause significant disability through mass effect, contracture formation, and nerve compression[39]. The iliopsoas is the most common site for pseudotumor development, though they can develop in any muscle group[39]. Surgical excision is indicated for pseudotumors causing functional impairment or neurological complications, but such surgery should only be performed in major hemophilia centers with integrated multidisciplinary surgical teams capable of managing the complex operative bleeding[39].

Intracranial Hemorrhage: The Most Serious Manifestation

Intracranial hemorrhage (ICH) represents the most life-threatening manifestation of hemophilia B, with mortality rates approximating 20 percent despite modern treatment[38][41]. ICH accounts for 3-4 percent of hemophilia B presentations at birth and constitutes a leading cause of morbidity and mortality in hemophilia patients of all ages[9][38][58]. The vast majority of ICH cases occur in patients with severe hemophilia B, though spontaneous ICH can occasionally occur in moderate disease[38][42]. In neonates and infants with severe hemophilia, ICH can present without obvious precipitating trauma, though delivery complications, subgaleal bleeding, and cephalohematomas are documented triggers[9][58]. In older children and adults, ICH may be triggered by minor head trauma in severe hemophilia but requires more significant trauma in moderate disease[38][42].

Intracranial hemorrhage in hemophilia B pathophysiologically results from bleeding into the epidural, subdural, or subarachnoid spaces, or into the brain parenchyma itself, owing to inadequate thrombin generation in response to vascular disruption[38][58]. The confined space of the cranial vault means that even modest amounts of bleeding create significant pressure elevation, potentially causing midline shift, herniation, and death[38][58]. Clinical presentation varies with the type and location of ICH but may include seizures, altered mental status, focal neurological deficits, headache, vomiting, and signs of increased intracranial pressure[38][58]. Prevention of ICH through early initiation of prophylactic factor replacement, ideally before age three years and prior to the second joint bleed, significantly reduces ICH incidence[59][38].

Additional Bleeding Manifestations: Gastrointestinal, Urinary Tract, and Mucosal Bleeding

Beyond joint and muscle bleeding, hemophilia B can present with bleeding into virtually any tissue. Gastrointestinal hemorrhage including hematemesis (vomiting blood) and melena (tarry stool) represent potentially serious bleeding manifestations that can result in significant blood loss and anemia[9][57][60]. Intramural hematoma of the gastrointestinal tract, in which bleeding occurs within the wall of the intestine, can present with acute abdomen, bloody stool, and paralytic ileus, potentially requiring surgical intervention though conservative management with factor replacement is generally preferred[57]. Hematuria (blood in urine) occurs when bleeding happens in the kidneys or urinary tract and may or may not be associated with flank pain depending on the bleeding location[9][60].

Spontaneous epistaxis (nosebleeds), bleeding from the oral mucosa and gums, and prolonged bleeding following dental procedures represent common mucosal bleeding manifestations[9][10]. Gastrointestinal and urinary tract hemorrhage, though serious, often respond well to aggressive factor replacement combined with antifibrinolytic therapy[60]. The application of local hemostatic measures including ice for mucosal bleeding, compression for accessible hemorrhage, and antifibrinolytic agents like aminocaproic acid can enhance hemostasis when combined with systemic factor replacement[5][10][60].

Complication Development: Inhibitor Formation and Its Immunological Basis

Factor IX Inhibitor Epidemiology and Immunological Mechanisms

One of the most serious complications affecting patients with hemophilia B is the development of inhibitory antibodies (inhibitors) to factor IX replacement therapy, which occurs in approximately 3-5 percent of hemophilia B patients with severe disease[9][23][30]. These inhibitors represent neutralizing IgG alloantibodies that bind to infused factor IX and block its biological activity, rendering replacement therapy ineffective and dramatically complicating bleeding management[9][23]. The prevalence of inhibitors in hemophilia B is substantially lower than in hemophilia A (5-10 percent), reflecting differences in the immunogenicity of the two factor proteins and the mutation types typically associated with each disease[4][23][30].

The development of factor IX inhibitors is strongly associated with specific mutation types, particularly large deletions, nonsense mutations, and some frameshift mutations that produce null mutations preventing any FIX protein synthesis[1][23]. Approximately 70 percent of hemophilia B patients who develop inhibitors carry high-risk mutations including large deletions or nonsense mutations[1][23][30]. Missense mutations, which produce structurally altered but still-present FIX protein, carry much lower inhibitor risk and rarely cause inhibitor formation except in rare cases[1][4]. This genotype-inhibitor association reflects the immunological principle that exposure to completely foreign proteins (those with major structural differences) triggers stronger immune responses than exposure to minimally altered self-proteins[1][23][30].

The immunological mechanism driving inhibitor development involves recognition of infused factor IX as a foreign antigen by the adaptive immune system, particularly in patients whose bodies have never produced normal FIX protein[23]. The "danger signal" hypothesis proposes that early infusion of factor VIII or factor IX in the absence of tissue injury-associated danger signals may actually prevent inhibitor development, whereas infusion in the context of bleeding with associated inflammation and cellular damage promotes immune responses[23]. Supporting evidence comes from the CANAL cohort demonstrating that regular prophylaxis was associated with a 60 percent lower risk of inhibitor development compared to on-demand treatment[23].

A particularly concerning aspect of factor IX inhibitor formation is the development of anaphylactoid reactions in up to 60 percent of patients with factor IX inhibitors, in contrast to the rarity of anaphylaxis in hemophilia A inhibitor patients[1][9][23]. These allergic reactions can range from mild urticaria to severe anaphylaxis with cardiovascular collapse and death[1][23][30]. The mechanism underlying this differential anaphylaxis risk in hemophilia B remains incompletely understood but may relate to the immunoglobulin isotype distribution of inhibitors or specific epitopes recognized by B cells in hemophilia B[1][23]. Patients developing anaphylactoid reactions to factor IX require desensitization protocols before attempting immune tolerance induction therapy[23].

Immune Tolerance Induction: Mechanisms and Limitations

Immune tolerance induction (ITI) therapy attempts to induce immunological tolerance to infused factor IX through repeated exposure to high-dose factor in the context of immunosuppressive or tolerogenic interventions[23][59]. Various ITI regimens have been studied, including high-dose factor with IVIG and cyclophosphamide, with reported success rates ranging from 59-82 percent[23]. However, the success rate of ITI in hemophilia B patients is substantially lower than in hemophilia A patients, with only approximately 30-50 percent of hemophilia B inhibitor patients achieving successful tolerance induction[23][30].

The limited success of ITI in hemophilia B reflects the immunological difficulty in tolerizing against large deletions and nonsense mutations producing structurally very different or absent FIX proteins[23]. Desensitization protocols may be necessary for patients with anaphylactoid reactions prior to attempting ITI[23][30]. Immune tolerance induction is not pursued by all patients due to the significant time and cost burden, with some patients choosing to rely instead on bypassing agents such as activated prothrombin complex concentrate (aPCC) or recombinant activated factor VIIa for bleeding management[23][30][59].

Sex-Specific and Age-Related Aspects of Hemophilia B Pathophysiology

X-Linked Inheritance and Its Consequences for Male and Female Patients

Hemophilia B follows an X-linked recessive inheritance pattern, with the F9 gene located on the lower portion of the X chromosome that lacks a corresponding locus on the Y chromosome[5][10][53]. This inheritance pattern has profound consequences for disease expression and transmission. Males, possessing only one X chromosome inherited from their mother, have only one copy of the F9 gene and consequently develop hemophilia B if that single X chromosome carries a hemophilia allele[5][10][53]. Females, inheriting two X chromosomes (one from each parent), require two copies of hemophilia alleles to develop hemophilia B, a situation occurring only when both parents carry the defective allele—an extremely rare circumstance[5][10][53].

However, the conventional understanding that carrier females remain asymptomatic requires substantial revision based on contemporary understanding of X-chromosome inactivation (lyonization). During early fetal development, each female cell undergoes random inactivation of one X chromosome, with the inactive X becoming a heterochromatin structure called a Barr body[40][53]. Normally, this process is random, resulting in approximately 50 percent of cells maintaining the maternal X chromosome and 50 percent maintaining the paternal X chromosome as active[40][53]. In heterozygous females carrying one hemophilia allele and one normal allele, this 50-50 distribution means that approximately half of hepatic cells (where FIX is synthesized) express normal FIX and half express defective or no FIX, resulting in approximately 50 percent of normal factor IX levels[5][37][40].

In some female carriers, however, the lyonization process becomes "skewed," with preferential inactivation of one X chromosome in most cells[40][53]. If the X chromosome carrying the normal FIX allele becomes preferentially inactivated through skewed lyonization, a carrier female may produce predominantly defective FIX and consequently develop a hemophilia B bleeding phenotype[5][40]. Carriers with skewed X-inactivation toward the defective allele can present with factor levels ranging from less than 1 percent to levels insufficient to prevent all bleeding, and such women experience bleeding symptoms identical to males with similar factor levels[5][37][40]. Furthermore, many female carriers with low factor expression experience heavy menstrual bleeding, easy bruising, and joint bleeds; some develop target joints identical to those seen in males with hemophilia[5][37].

Age and Disease Progression: Different Bleeding Patterns Across the Lifespan

The clinical manifestations of hemophilia B change throughout the lifespan, with infants and young children presenting with different bleeding patterns than older adolescents and adults[9][36][58]. In infants with severe hemophilia B, bleeding may occur after circumcision (though some infants are diagnosed through family history or screening without any bleeding), and intramuscular vaccinations may trigger muscle hematomas[9][58][60]. As infants become mobile, bleeding into joints occurs with increasing frequency as minor traumatic events inevitable in learning to walk trigger hemarthrosis[9][58]. Intracranial hemorrhage risk is highest in the neonatal and early infancy period, with 3-4 percent of hemophilia B patients experiencing ICH at birth[9][58].

Joint bleeding rates show characteristic age variation, with peak bleeding frequency occurring in the 10-24 year age group and again in the 25-44 year age group[36]. This age-related pattern reflects increased physical activity and sports participation in adolescents and young adults, combined with ongoing degenerative changes in joints already damaged by prior hemarthrosis in older adults[36]. Data from the Universal Data Collection program demonstrate that hemophilia B patients with similar factor levels experience substantially different bleeding rates depending on age, with young adults experiencing higher hemarthrosis frequencies than children or older individuals[36].

Women with hemophilia B face unique challenges related to menstruation, pregnancy, and postpartum bleeding. Women with moderate-to-severe hemophilia often experience menorrhagia (heavy menstrual bleeding) if their factor levels are sufficiently reduced, and some require hormonal contraception or prophylactic factor infusions during menses[5][10]. Pregnancy presents particular complexity because some hemophilic women experience significant improvement in factor levels during pregnancy (as pregnancy-associated stress can drive compensatory synthesis), while others maintain low levels throughout pregnancy[5][10]. Postpartum hemorrhage risk is elevated in women with significant factor deficiency, necessitating peripartum factor replacement and monitoring[5][10].

Recent Therapeutic Advances Reshaping Hemophilia B Pathophysiology Management

Gene Therapy: Introducing a Functional F9 Gene via Adeno-Associated Vectors

Adeno-associated virus (AAV)-based gene therapy represents a transformative approach to hemophilia B pathophysiology management by introducing a functional copy of the F9 gene directly into patients' hepatocytes, allowing endogenous production of factor IX without continued dependence on intravenous infusion[25][28]. Multiple AAV-based gene therapies have completed clinical trials with encouraging results demonstrating sustained FIX expression and significant reduction in annualized bleeding rates and factor infusion requirements[25][28]. A systematic review and meta-analysis examining 12 hemophilia B trials enrolling 184 patients found mean factor IX levels at 12 months of 28.72 IU/mL, with factor expression being notably more durable for hemophilia B than hemophilia A, with FIX levels remaining at 95.7 percent of peak at 24 months[25].

In 2022, the FDA approved etranacogene dezaparovovec (Hemgenix), an AAV5-based vector containing the F9-Padua variant, a naturally occurring gain-of-function mutation (R338L) that increases specific FIX activity by 4- to 40-fold, enabling significant therapeutic benefit even at lower transgene expression levels[30][43]. This gain-of-function approach addresses a critical limitation of earlier AAV vectors in achieving sufficient FIX levels through dose-escalation while avoiding hepatic toxicity from high vector capsid loads[43][46]. The R338L variant increases FIX specific activity 6-fold or greater compared to wild-type FIX while maintaining normal regulation by endogenous anticoagulants[43][46].

However, AAV-based gene therapy faces important challenges relevant to understanding disease pathophysiology management. Preexisting neutralizing antibodies to AAV vectors can eliminate therapeutic efficacy; studies show that higher pre-existing NAb titers prevent transgene expression even though higher vector doses can overcome moderate titers[28]. The cellular immune response to AAV capsid proteins has limited some patients' transgene expression through mechanisms involving rise in transaminases, decline in factor activity, and clearance of transduced hepatocytes[28]. Importantly, gene therapy has introduced novel safety concerns including rare cases of hepatocellular carcinoma development in patients with longstanding hepatitis C infection[28]. Additionally, one patient achieving supraphysiologic FIX activity (200-520 percent) developed thrombosis in an arteriovenous fistula, suggesting a therapeutic window exists that extends to the upper limit of normal but not beyond[28].

Non-Factor Replacement Strategies: Rebalancing the Coagulation Cascade

Beyond factor replacement and gene therapy, emerging therapeutic strategies target anticoagulant proteins to rebalance dysregulated coagulation. Tissue factor pathway inhibitor (TFPI) represents a key anticoagulant that suppresses early stages of coagulation by inhibiting the TF-FVIIa complex and early forms of prothrombinase[51][54]. TFPI inhibition aims to enhance hemostasis through rebalancing by enabling the extrinsic and common pathways to function more efficiently despite the absence of FIX[51][54]. Because TFPI is a major physiological regulator of bleeding in hemophilia, selective inhibition of platelet TFPI (rather than endothelial TFPI) may provide optimal therapeutic benefit while minimizing thrombotic risk[51][54].

Concizumab, a monoclonal antibody targeting TFPI, represents a TFPI-inhibition strategy under investigation for hemophilia B[30][51]. Other approaches under development include emicizumab, a bispecific antibody replacing the cofactor role of factor VIII in bridging activated factor IX to activate factor X[59]. While emicizumab is currently FDA-approved for hemophilia A prophylaxis with or without inhibitors, the potential for similar approaches targeting the factor IX pathway remains under exploration for hemophilia B[59].

Chemical Chaperones and Protein Misfolding Correction

An alternative molecular mechanism for treating some hemophilia B variants involves correction of protein misfolding in the endoplasmic reticulum. Chemical chaperones such as betaine promote protein folding and enhance secretion of misfolded FIX proteins into plasma[18]. Studies in hemophilia A demonstrate that betaine feeding significantly increases FVIII secretion in vitro and in vivo[18]. While fewer studies have examined betaine effects in hemophilia B, the principle of correcting protein misfolding through chemical chaperone supplementation represents a potential therapeutic avenue for hemophilia B patients with missense mutations causing ER retention of FIX protein[18].

Conclusion: Integrating Molecular Understanding with Clinical Practice

Hemophilia B pathophysiology represents a paradigm of how a single gene defect produces a systemic cascade of consequences affecting hemostasis, with disease expression ranging from asymptomatic carrier states to life-threatening spontaneous hemorrhage. The F9 gene mutations causing hemophilia B operate through multiple distinct mechanisms—complete loss of protein synthesis through nonsense and frameshift mutations, production of functionally defective proteins through missense mutations, impaired post-translational modification through propeptide mutations, and dysregulated gene expression through promoter mutations. These diverse genetic mechanisms converge on a common functional outcome: insufficient factor IX in the circulation to generate adequate thrombin through the intrinsic tenase complex, resulting in inadequate amplification of coagulation and clinical bleeding.

The intrinsic pathway deficiency underlying hemophilia B becomes clinically manifest through tissue-specific bleeding patterns reflecting local tissue factor expression and hemodynamic factors. Joints and skeletal muscles, with low tissue factor expression and susceptibility to microvascular injury, become primary bleeding sites where the intrinsic pathway's critical amplification role becomes physiologically essential. The recurrent hemarthrosis characteristic of severe hemophilia B initiates a vicious cycle of inflammation, iron-mediated oxidative damage, and progressive joint destruction that ultimately produces hemophilic arthropathy—the primary cause of morbidity in hemophilia B.

Contemporary management of hemophilia B is rapidly evolving toward curative approaches including gene therapy that addresses the fundamental F9 gene defect through hepatocyte-directed transgene delivery. The approval of AAV-based gene therapy containing the F9-Padua gain-of-function variant represents a watershed moment in hemophilia medicine, potentially offering one-time treatment converting severe hemophilia B to a mild or asymptomatic state. However, the limitations of current gene therapy, including neutralizing antibody exclusions and rare but serious adverse events, underscore the continued need for improved therapeutic approaches and deeper understanding of how the immune system responds to gene delivery vectors.

The emerging class of non-factor replacement strategies targeting anticoagulant proteins offers mechanistically distinct therapeutic approaches that bypass the missing factor entirely through rebalancing the procoagulant-anticoagulant equilibrium. These approaches promise to eliminate factor inhibitor complications and reduce treatment burden through less frequent dosing or single administrations. As hemophilia B therapeutics continue to advance toward curative modalities, the pathophysiological framework presented here—linking genetic mutation to protein dysfunction to hemostatic impairment to clinical manifestation—remains essential for understanding disease biology, predicting treatment responses, and guiding the development of next-generation therapies addressing remaining unmet clinical needs in this complex bleeding disorder.